NCT06391892 Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
| NCT ID | NCT06391892 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Elisabethinen Hospital |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-01-11 |
| Primary Completion | 2025-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.
Eligibility Criteria
Inclusion Criteria: * Informed consent * \>18 years old * localized pancreatic cancer to go for upfront surgery Exclusion Criteria: * synchronous secondary malignancy * pregnancy
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.